{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IT+Injection&page=25",
    "query": {
      "intervention": "IT Injection",
      "page": 25
    },
    "page_size": 10
  },
  "pagination": {
    "page": 25,
    "page_size": 10,
    "total_count": 708,
    "total_pages": 71,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IT+Injection&page=26&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IT+Injection&page=24&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-24T16:21:05.567Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05133739",
      "title": "RHA®4 for Midface Volume Deficiency",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [],
      "conditions": [
        "Cheek Augmentation",
        "Correction of Age-related Midface Contour Deficiencies"
      ],
      "interventions": [
        {
          "name": "injection of RHA®4 in Midface",
          "type": "DEVICE"
        },
        {
          "name": "injection of Comparator Product in Midface",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Teoxane SA",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "22 Years and older"
      },
      "enrollment_count": 201,
      "start_date": "2021-10-29",
      "completion_date": "2024-01-29",
      "has_results": true,
      "last_update_posted_date": "2025-03-18",
      "last_synced_at": "2026-10-24T16:21:05.567Z",
      "location_count": 1,
      "location_summary": "Chestnut Hill, Massachusetts",
      "locations": [
        {
          "city": "Chestnut Hill",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05133739"
    },
    {
      "nct_id": "NCT04167137",
      "title": "Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Solid Neoplasm",
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "SYNB1891",
          "type": "DRUG"
        },
        {
          "name": "Atezolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Synlogic",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2019-12-12",
      "completion_date": "2021-12-09",
      "has_results": true,
      "last_update_posted_date": "2024-05-03",
      "last_synced_at": "2026-10-24T16:21:05.567Z",
      "location_count": 6,
      "location_summary": "Aurora, Colorado • Hackensack, New Jersey • Columbus, Ohio + 3 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04167137"
    },
    {
      "nct_id": "NCT04220866",
      "title": "Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Head and Neck Squamous Cell Carcinoma (HNSCC)"
      ],
      "interventions": [
        {
          "name": "Ulevostinag",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2020-03-04",
      "completion_date": "2022-09-30",
      "has_results": true,
      "last_update_posted_date": "2025-10-29",
      "last_synced_at": "2026-10-24T16:21:05.567Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • San Francisco, California • Detroit, Michigan + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Sioux Falls",
          "state": "South Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04220866"
    },
    {
      "nct_id": "NCT05106192",
      "title": "Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System.",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Mycosis Fungoides of Skin (Diagnosis)",
        "Cutaneous T-cell Lymphoma",
        "Non Hodgkin Lymphoma",
        "Lymphomatoid Papulosis",
        "Lymphoma, Large-Cell, Anaplastic",
        "Lymphoma, Follicular"
      ],
      "interventions": [
        {
          "name": "Med-Jet Injector",
          "type": "DEVICE"
        },
        {
          "name": "Triamcinolone Acetonide",
          "type": "DRUG"
        },
        {
          "name": "Bexarotene 1% Top Gel",
          "type": "DRUG"
        },
        {
          "name": "Nitrogen Mustard",
          "type": "DRUG"
        },
        {
          "name": "Conventional syringe",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2022-04-01",
      "completion_date": "2026-06-01",
      "has_results": false,
      "last_update_posted_date": "2025-06-12",
      "last_synced_at": "2026-10-24T16:21:05.567Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05106192"
    },
    {
      "nct_id": "NCT03122119",
      "title": "Effectiveness of Ultrasound Guided Platelet Rich Plasma Injections in the Sacroiliac Joint",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Low Back Pain",
        "Sacroiliitis",
        "Sacroiliac; Backache",
        "Platelet Rich Plasma",
        "Platelet",
        "Injection Site",
        "Ultrasound Therapy; Complications",
        "Treatment"
      ],
      "interventions": [
        {
          "name": "Platelet Rich Plasma Joint Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Star Spine and Sport",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 51,
      "start_date": "2017-05-01",
      "completion_date": "2022-09-01",
      "has_results": true,
      "last_update_posted_date": "2023-04-28",
      "last_synced_at": "2026-10-24T16:21:05.567Z",
      "location_count": 1,
      "location_summary": "Golden, Colorado",
      "locations": [
        {
          "city": "Golden",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03122119"
    },
    {
      "nct_id": "NCT04023019",
      "title": "Treatment of Hemophilia A Patients With FVIII Inhibitors",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hemophilia A"
      ],
      "interventions": [
        {
          "name": "Nuwiq",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Octanate",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Wilate",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Emicizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Recombinant factor VIIa (rFVIIa)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Activated prothrombin complex concentrate (aPCC)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 120,
      "start_date": "2020-03-17",
      "completion_date": "2029-06",
      "has_results": false,
      "last_update_posted_date": "2026-09-23",
      "last_synced_at": "2026-10-24T16:21:05.567Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04023019"
    },
    {
      "nct_id": "NCT03927651",
      "title": "ICG to Assess Ovarian Perfusion",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Fibroid Uterus",
        "Endometriosis",
        "Uterus Myoma",
        "Uterine Fibroid",
        "Uterine Adenomyosis",
        "Endometrial Cyst",
        "Uterine Cyst"
      ],
      "interventions": [
        {
          "name": "ICG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwestern University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 54,
      "start_date": "2019-06-01",
      "completion_date": "2022-11-15",
      "has_results": false,
      "last_update_posted_date": "2023-04-18",
      "last_synced_at": "2026-10-24T16:21:05.567Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03927651"
    },
    {
      "nct_id": "NCT02076022",
      "title": "AMP30: Autologous Fat Grafting, Amputation Sites Pain: Randomized",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Wounded Warrior",
        "Limb Shortening",
        "Amputation"
      ],
      "interventions": [
        {
          "name": "Enhanced Fat Grafting",
          "type": "DEVICE"
        },
        {
          "name": "Standard fat graft",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "PROCEDURE"
      ],
      "sponsor": "J. Peter Rubin, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2014-04-08",
      "completion_date": "2019-01-28",
      "has_results": true,
      "last_update_posted_date": "2020-11-10",
      "last_synced_at": "2026-10-24T16:21:05.567Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02076022"
    },
    {
      "nct_id": "NCT03984045",
      "title": "SPG Block for Acute Pediatric Migraine",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Migraine in Children",
        "Sphenopalatine Neuralgia",
        "Migraine in Adolescence"
      ],
      "interventions": [
        {
          "name": "Lidocaine topical",
          "type": "DRUG"
        },
        {
          "name": "Prochlorperazine Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Newark Beth Israel Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "20 Years",
        "sex": "ALL",
        "summary": "10 Years to 20 Years"
      },
      "enrollment_count": 72,
      "start_date": "2019-06-06",
      "completion_date": "2022-12-30",
      "has_results": false,
      "last_update_posted_date": "2021-11-17",
      "last_synced_at": "2026-10-24T16:21:05.567Z",
      "location_count": 1,
      "location_summary": "Newark, New Jersey",
      "locations": [
        {
          "city": "Newark",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03984045"
    },
    {
      "nct_id": "NCT04615013",
      "title": "NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cervical Esophagus Adenocarcinoma",
        "Clinical Stage II Esophageal Adenocarcinoma AJCC v8",
        "Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8",
        "Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8",
        "Clinical Stage III Esophageal Adenocarcinoma AJCC v8",
        "Gastroesophageal Junction Adenocarcinoma",
        "Pathologic Stage II Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage III Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8",
        "Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8",
        "Thoracic Esophagus Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Capecitabine",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Hafnium Oxide-containing Nanoparticles NBTXR3",
          "type": "OTHER"
        },
        {
          "name": "Intensity-Modulated Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "RADIATION"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2020-11-23",
      "completion_date": "2027-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-07",
      "last_synced_at": "2026-10-24T16:21:05.567Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04615013"
    }
  ]
}